In this video, health-care analyst David Williamson discusses two cutting-edge but very different hepatitis C drug candidates under FDA review. A little less than a month ago, Johnson & Johnson received priority status for its simeprevir, shortening its decision time by four months.
Investors recently learned that Gilead also received priority status for its entry sofosbuvir. Watch and find out why Gilead is set to change the entire treatment paradigm for this disease and why approval for Gilead may be a boost for J&J.
